Working... Menu
Trial record 89 of 200 for:    aspergillosis

Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00923832
Recruitment Status : Completed
First Posted : June 18, 2009
Last Update Posted : July 2, 2017
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:


  • Fungal infections of the lung (pneumonia) can be caused by molds, such as Aspergillus and Zygomycetes, but these causes are often difficult for a doctor to diagnose. Early and accurate diagnosis of these infections can help doctors to select the correct medicines for proper treatment.
  • A number of methods are used to diagnose fungal pneumonia. Ones that are commonly used in clinical practice include radiographic imaging (chest X-rays and computed tomography (CT) scans), blood tests, and cultures taken from fluid from the lungs (broncho-alveolar lavage (BAL) fluid). Other new methods may improve the diagnosis of fungal pneumonias. These methods include tests that can detect DNA from the fungal germ in blood and BAL fluid of some patients with these infections.


  • To help develop better and more accurate methods of diagnosing fungal lung infections.
  • To detect fungal DNA and chemicals in the bloodstream and BAL fluid of immunocompromised patients with pneumonia.


- Immunocompromised patients who are currently enrolled in another NIH protocol and who have a CT scan that shows a possible fungal infection of the lung.


  • Researchers will review patients' existing medical records and CT scans, and current pneumonia treatment plans.
  • Patients will provide blood and BAL samples for the duration of their treatment for pneumonia, as required by researchers. Additional CT scans will not be performed, except as part of existing treatment plans.

Condition or disease
Immunocompromised Host Invasive Pulmonary Fungal Infection Invasive Pulmonary Aspergillosis Invasive Pulmonary Zygomycosis

  Show Detailed Description

Layout table for study information
Study Type : Observational
Time Perspective: Prospective
Official Title: Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis
Study Start Date : March 30, 2009
Study Completion Date : November 23, 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aspergillosis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Patients currently enrolled in any NIH IRB approved Clinical Center protocol or under treatment at the CNMC who are undergoing bronchoscopy or lung biopsy for diagnosis of possible invasive pulmonary aspergillosis or invasive pulmonary zygomycosis.

Informed consent of the patient or the patient's legally authorized representative.

Fulfillment of one or more of the following EORTC/MSG host criteria:

  • History of neutropenia (ANC < 500/mm(3)) within the past 3 months temporally related to the onset of radiographic changes
  • Receipt of an allogeneic HSCT
  • Receipt of solid organ transplantation
  • Prolonged use of corticosteroids at an average minimum dose of 0.3 mg/kg/day prednisone equivalent for > 3 weeks
  • Treatment with other recognized T-cell immune suppressants such as cyclosporine, TNF alpha blockers, specific monoclonal antibodies such as alemtuzumab, nucleoside analogues during the past 90 days
  • Myelodysplastic syndrome
  • Severe aplastic anemia
  • Cushing's disease
  • Primary immunodeficiencies (such as chronic granulomatous disease, severe combined immunodeficiency)

The presence of one or more of the following signs on chest CT or radiograph:

  • Dense well circumscribed lesions with or without a halo sign
  • Air crescent sign
  • Cavity
  • Focal, segmental or lobar infiltrates


Interstitial or diffuse infiltrates on chest CT or radiograph

Inability to provide informed consent

Children weighing less than 10 kg

Any other concomitant condition, which in the opinion of the investigator would place the patient at risk by participating in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00923832

Layout table for location information
United States, District of Columbia
Childrens National Medical Center
Washington, D.C., District of Columbia, United States
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)

Layout table for additonal information Identifier: NCT00923832     History of Changes
Other Study ID Numbers: 090109
First Posted: June 18, 2009    Key Record Dates
Last Update Posted: July 2, 2017
Last Verified: November 23, 2009

Keywords provided by National Institutes of Health Clinical Center (CC):
Fungal Infections
PCR Assays
Cell Wall Derived Biomarkers
EORTC/MSG Definitions
Molecular Assays
Lung Fungal Infection
Invasive Pulmonary Fungal Infection
Invasive Pulmonary Aspegillosis
Invasive Pulmonary Zycomycosis

Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Aspergillosis
Invasive Pulmonary Aspergillosis
Lung Diseases, Fungal
Lung Diseases
Respiratory Tract Diseases
Invasive Fungal Infections
Respiratory Tract Infections